MiNK Therapeutics (INKT) Competitors $7.63 -0.20 (-2.55%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$8.12 +0.50 (+6.49%) As of 04/17/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. LRMR, ADCT, THTX, CGEN, MCRB, KOD, CHRS, FTLF, EPRX, and EDITShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Larimar Therapeutics (LRMR), ADC Therapeutics (ADCT), Theratechnologies (THTX), Compugen (CGEN), Seres Therapeutics (MCRB), Kodiak Sciences (KOD), Coherus BioSciences (CHRS), FitLife Brands (FTLF), Eupraxia Pharmaceuticals (EPRX), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Larimar Therapeutics ADC Therapeutics Theratechnologies Compugen Seres Therapeutics Kodiak Sciences Coherus BioSciences FitLife Brands Eupraxia Pharmaceuticals Editas Medicine Larimar Therapeutics (NASDAQ:LRMR) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation. Which has stronger valuation and earnings, LRMR or INKT? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.30-1.47MiNK TherapeuticsN/AN/A-$22.46M-$2.92-2.61 Does the media prefer LRMR or INKT? In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 1 articles in the media. Larimar Therapeutics' average media sentiment score of 1.34 beat MiNK Therapeutics' score of 1.00 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Larimar Therapeutics Positive MiNK Therapeutics Positive Does the MarketBeat Community believe in LRMR or INKT? Larimar Therapeutics received 29 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 77.27% of users gave MiNK Therapeutics an outperform vote while only 71.88% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% MiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% Do analysts recommend LRMR or INKT? Larimar Therapeutics presently has a consensus target price of $19.63, suggesting a potential upside of 930.18%. MiNK Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 391.48%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in LRMR or INKT? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 3.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is LRMR or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% MiNK Therapeutics N/A N/A -189.14% Which has more risk and volatility, LRMR or INKT? Larimar Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. SummaryLarimar Therapeutics beats MiNK Therapeutics on 11 of the 15 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.26M$2.84B$5.30B$7.35BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-1.9630.4821.8017.80Price / SalesN/A441.91379.9697.74Price / CashN/A168.6838.2634.64Price / Book-1.463.466.443.98Net Income-$22.46M-$72.06M$3.21B$247.73M7 Day Performance-8.29%2.58%2.88%1.81%1 Month Performance-7.40%-15.68%-8.63%-6.98%1 Year Performance-12.47%-26.09%11.46%1.29% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics3.0929 of 5 stars$7.63-2.6%$37.50+391.5%-16.6%$30.26MN/A-1.9630Short Interest ↓Positive NewsGap DownLRMRLarimar Therapeutics3.2344 of 5 stars$1.87+3.3%$19.63+949.5%-73.0%$119.73MN/A-1.6330Positive NewsADCTADC Therapeutics2.1826 of 5 stars$1.21-1.2%$7.75+543.2%-75.4%$119.40M$70.84M-0.50310THTXTheratechnologiesN/A$2.57+32.5%N/A+88.1%$118.17M$85.87M-25.70140Analyst RevisionNews CoverageHigh Trading VolumeCGENCompugen1.2835 of 5 stars$1.31+4.0%$4.00+205.3%-22.6%$116.90M$27.86M65.5070Gap UpMCRBSeres Therapeutics3.0343 of 5 stars$0.66+12.3%$4.00+503.0%-41.0%$115.65M$126.33M-2.88330News CoverageGap UpKODKodiak Sciences3.4934 of 5 stars$2.18flat$9.00+312.8%-21.0%$114.99MN/A-0.6090Short Interest ↑Analyst RevisionGap UpCHRSCoherus BioSciences3.618 of 5 stars$0.97+16.6%$5.38+451.5%-47.9%$112.95M$266.96M-12.18330Analyst DowngradeNews CoverageGap DownFTLFFitLife Brands4.2338 of 5 stars$12.07+3.3%$20.50+69.8%-9.9%$111.27M$64.47M14.2820EPRXEupraxia Pharmaceuticals1.7821 of 5 stars$3.10+2.3%$10.50+238.7%+25.4%$111.13MN/A-4.3129EDITEditas Medicine4.0135 of 5 stars$1.32+1.5%$6.83+417.7%-77.1%$110.50M$32.31M-0.52230Analyst RevisionNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies Larimar Therapeutics Competitors ADC Therapeutics Competitors Theratechnologies Competitors Compugen Competitors Seres Therapeutics Competitors Kodiak Sciences Competitors Coherus BioSciences Competitors FitLife Brands Competitors Eupraxia Pharmaceuticals Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INKT Stock Free INKT Stock Alerts